|
Take heed to this text |
Bionaut Labs, a robotic drug supply expertise developer, closed a Collection B financing spherical value $43.2 million. Los Angeles-based Bionaut Labs makes use of microscale robots to ship medicine for treating central nervous system (CNS) ailments and issues. By means of magnetic propulsion, the corporate’s Bionauts can navigate the human physique and ship medicine regionally.
The expertise can attain deep areas within the midbrain with precision, going past the blood-brain barrier. This generates effectivity and helps to keep away from unwanted side effects and toxicity from systemically delivered medicine. Bionaut goals to develop options for situations together with Parkinson’s illness, Huntington’s illness, malignant glioma and hydrocephalus.
Funds raised within the Collection B spherical are earmarked for advancing the scientific growth of Bionaut’s lead packages. These packages embody therapies for malignant glioma mind tumors and Dandy-Walker Syndrome (a uncommon pediatric neurological dysfunction). The corporate additionally plans to make use of funds to help additional growth of the proprietary Bionaut therapy platform.

Bionaut plans to launch main pre-clinical information packages from IDE- and IND-enabling research in 2023. It goals to provoke human scientific trials in 2024.
Khosla Ventures led the financing, bringing Bionaut’s funds raised to this point to $63.2 million. New traders Deep Perception, OurCrowd, PSPRS, Sixty Diploma Capital, Dolby Household Ventures, GISEV Household Ventures, What if Ventures, Tintah Grace and Gaingels participated. Current traders Upfront Ventures, BOLD Capital Companions, Revolution VC, and Compound additionally participated.
“There was a dearth of innovation round therapies for situations that trigger great struggling, largely as a result of previous failures have discouraged even the very best of researchers,” stated Michael Shpigelmacher, co-founder and CEO, Bionaut Labs. “Bionaut Labs stays dedicated to discovering new methods to deal with these devastating ailments, that are lengthy overdue for a breakthrough.”

